Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of secondary cytoreduction in relapsed ovarian cancer.
Gouveia MC, Shinkado YR, Rossi AJ, Baiocchi G, Scaranti M. Gouveia MC, et al. Int J Gynecol Cancer. 2024 Nov 4;34(11):1834-1835. doi: 10.1136/ijgc-2024-005876. Int J Gynecol Cancer. 2024. PMID: 39089730 No abstract available.
The intriguing overall survival results of the PRIMA trial.
Gouveia MC, Leis LV, Graziano LM, Scaranti M. Gouveia MC, et al. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-006187. doi: 10.1136/ijgc-2024-006187. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39433421 No abstract available.
Task force of the Brazilian Society of Otology - evaluation and management of peripheral facial palsy.
Pauna HF, Silva VAR, Lavinsky J, Hyppolito MA, Vianna MF, Gouveia MCL, Monsanto RDC, Polanski JF, Silva MNLD, Soares VYR, Sampaio ALL, Zanini RVR, Abrahão NM, Guimarães GC, Chone CT, Castilho AM. Pauna HF, et al. Among authors: gouveia mcl. Braz J Otorhinolaryngol. 2024 May-Jun;90(3):101374. doi: 10.1016/j.bjorl.2023.101374. Epub 2023 Dec 8. Braz J Otorhinolaryngol. 2024. PMID: 38377729 Free PMC article. Review.
Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors.
Gouveia MC, Amorim de Araújo Lima Santos C, Impieri Souza A. Gouveia MC, et al. Contemp Clin Trials Commun. 2022 Oct 8;30:101013. doi: 10.1016/j.conctc.2022.101013. eCollection 2022 Dec. Contemp Clin Trials Commun. 2022. PMID: 36262803 Free PMC article.
17 results